Clinical Trial Detail

NCT ID NCT03516617
Title Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

CLL/SLL

Therapies

Acalabrutinib

Acalabrutinib + Obinutuzumab

Age Groups: adult senior

No variant requirements are available.